Bambusa Therapeutics, Inc. Form 424B4 — Oct 30, 2026
Bambusa Therapeutics priced its IPO at $16.00 per share, selling 10,555,555 shares for gross proceeds of approximately $168.9 million ($152.4 million net), with shares set to trade on Nasdaq under ticker BBTX. Underwriters hold a 30-day option for up to 1,583,333 additional shares, and BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor led the deal. The company is a clinical-stage biotech developing long-acting bispecific antibodies for immunology and inflammation.
Key figures
- Total Assets
- 77496000
- Cash Position
- 71500000
- Gross Proceeds
- 168888880
- Offering Price
- 16
- Shares Offered
- 10555555
- Shares Outstanding
- 50942430
- Runway
- sufficient to fund operations into late 2028 post-offering
- Employees
- 30 full-time as of September 30, 2026
- Net proceeds
- $152.4 million ($176.0 million if greenshoe exercised in full)
- Nasdaq symbol
- BBTX
- Greenshoe shares
- 1583333
- Accumulated deficit
- $77.2 million as of June 30, 2026
- Forward stock split
- 1.54485-for-1 effected October 23, 2026
- Use of proceeds bbt001
- $90.0 million
- Use of proceeds bbt002
- $40.0 million
- Prior private financing
- $136.1 million gross
- Preliminary cash sept 30 2026
- $57.2 million
- Underwriting discount per share
- 1.12
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.